AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12401596
Drug: Caudal neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal neostigmine (2 micro g/kg in normal saline 1 mL/kg)
Trial: 8560532
Drug: Amodiaquine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (35 mg/kg over 3 days)
Trial: 2128475
Drug: Auranofin (AF)
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auranofin (AF) 6 mg/day
Trial: 2128475
Drug: Gold sodium
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold sodium thiomalate (GST) 50 mg/week
Trial: 2128475
Drug: Gold sodium
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold sodium thiomalate (GST) 50 mg/month after dose reduction
Trial: 2128475
Drug: Auranofin (AF)
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auranofin (AF) 4 mg/day after dose reduction
Trial: 28345162
Drug: Lixisenatide (10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide (10 µg initially increased weekly by 5 up to 20 µg)
Trial: 28345162
Drug: Sitagliptin (50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (50 mg once daily)
Trial: 26087566
Drug: Sophora gel
RxNorm normalized name: Sophora pachycarpa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sophora gel (one piece every night for 14 days) and Fluconazole capsules (150 mg, once every three days, four times in total)
Trial: 26087566
Drug: Fluconazole capsules
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole capsules (control group)
Trial: 26087566
Drug: Sophora gel
RxNorm normalized name: Sophora pachycarpa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sophora gel combined with Fluconazole capsules
Trial: 22837542
Drug: Early enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early enhanced speech and language therapy after stroke
Trial: 21860188
Drug: Amiodarone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (3 mg/kg in 100 ml normal saline)
Trial: 17485450
Drug: Morphine, atropine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine, atropine, and suxamethonium
Trial: 9593137
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of RMP plus 400 mg of OFLO and 100 mg of MINO
Trial: 9593137
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of OFLO plus 100 mg of MINO
Trial: 7923315
Drug: Clebopride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clebopride (0.5 mg) and simethicone (200 mg)
Trial: 3380312
Drug: Dantrolene sodium
RxNorm normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dantrolene sodium (25 mg, twice a day for seven days)
Trial: 21697532
Drug: MVA85A with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A with EPI vaccines
Trial: 21697532
Drug: EPI vaccines
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI vaccines alone
Trial: 19383885
Drug: High triglycerides
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High triglycerides (> or =136 mg/dL)
Trial: 11348910
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release oral morphine
Trial: 8489572
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fluconazole suppository
Trial: 8489572
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg fluconazole suppository
Trial: 8489572
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg and 25 mg fluconazole suppositories
Trial: 28961427
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (550 mg) and codeine phosphate (30 mg)
Trial: 28961427
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride (50 mg)
Trial: 12584785
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy of western medicine
Trial: 1283192
Drug: Nilvadipine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (16 mg q.d.)
Trial: 1283192
Drug: Hydrochlorothiazide/Triamterene (HCT/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide/Triamterene (HCT/T) (25/50 mg q.d.)
Trial: 1283192
Drug: Nilvadipine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (1 x 8 mg)
Trial: 1283192
Drug: Enalapril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (1 x 10 mg)
Trial: 3574642
Drug: 1.0 M
RxNorm normalized name: Syringe Filter 1.0 Micron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 M sodium lactate (5 ml/kg in 5% dextrose/water) over a 20‐min period
Trial: 26823970
Drug: Pragmatic advice,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pragmatic advice, manual soft tissue treatment and exercises
Trial: 26823970
Drug: Pragmatic advice,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pragmatic advice, manual soft tissue treatment and exercises plus manipulative therapy
Trial: 19045976
Drug: Acceptance-based behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based behavior therapy
Trial: 10652394
Drug: Propofol/fentanyl combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol/fentanyl combination
Trial: 9050095
Drug: Pressurized aerosol
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pressurized aerosol of ipratropium bromide (80 mg single dose)
Trial: 9050095
Drug: Aqueous pump
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous pump spray of ipratropium bromide (80 mg single dose)
Trial: 22268365
Drug: Irbesartan (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (overall treatment)
Trial: 18091016
Drug: GABA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA (3 g)
Trial: 14658966
Drug: High-dose divalproex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose divalproex sodium
Trial: 9065315
Drug: New formulation
RxNorm normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation of verapamil (Veramex 40)
Trial: 9065315
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation of verapamil
Trial: 23905576
Drug: Inhaled GS-9411
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhaled GS-9411 (2.4, 4.8, and 9.6 mg), dosed twice daily for 14 days
Trial: 23905576
Drug: Inhaled GS-9411
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhaled GS-9411
Trial: 21926426
Drug: Venlafaxine extended
RxNorm normalized name: Desvenlafaxine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine extended release (ER) 37.5 to 300 mg/day
Trial: 18824828
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/d
Trial: 12952496
Drug: BIA 2‐093
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 2‐093 (20, 50, 100, 200, 400, 600, 900, 1200 mg)
Trial: 9007129
Drug: Paclitaxel 185
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 185 mg/m2 and Carboplatin 350 mg/m2
Trial: 29563072
Drug: TIMBER-K (Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIMBER-K (Ketamine + TIMBER therapy)
Trial: 29563072
Drug: TIMBER-P (Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIMBER-P (Placebo + TIMBER therapy)
Trial: 27295296
Drug: Manual trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual trigger point compression therapy
Trial: 27295296
Drug: Manual sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual sham therapy
Trial: 24978857
Drug: MF59-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccine with 3.75 μg antigen
Trial: 24978857
Drug: MF59-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccine with 7.5 μg antigen
Trial: 24978857
Drug: Nonadjuvanted vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted vaccine with 15 μg antigen (for children 12-35 months only)
Trial: 24978857
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of MF59-adjuvanted seasonal influenza vaccine
Trial: 10794804
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron 1 mg twice daily
Trial: 10794804
Drug: Prochlorperazine 10
RxNorm normalized name: prochlorperazine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 10 mg sustained release capsule twice daily
Trial: 8989127
Drug: hBNP infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hBNP infusion (0.003, 0.01, 0.03, and 0.1 microgram/kg per minute)
Trial: 8989127
Drug: hBNP infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hBNP infusion
Trial: 30249940
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with atorvastatin and amlodipine
Trial: 28411114
Drug: Plasma biologically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma biologically active adrenomedullin (bio-ADM) on day 1 (median [Q1-Q3], 110 [59-198] pg/mL)
Trial: 28411114
Drug: bio-ADM trajectory
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bio-ADM trajectory during the first week of treatment
Trial: 28411114
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of bio-ADM below 110 pg/mL at day 7
Trial: 20029506
Drug: Quercetin 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 1000 mg.day(‐1) for 3 weeks
Trial: 11053509
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (200 mg ferrous sulfate)
Trial: 11053509
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly iron supplementation (2 x 200 mg ferrous sulfate)
Trial: 2979209
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg, 6-hourly, n = 8)
Trial: 2979209
Drug: Ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (50 mg, 6-hourly, n = 10)
Trial: 2979209
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (placebo, n = 12)
Trial: 2979209
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (gastric ulcer patients)
Trial: 20139391
Drug: Dasatinib 50
RxNorm normalized name: dasatinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 50 mg twice-daily
Trial: 20139391
Drug: Dasatinib 140
RxNorm normalized name: dasatinib 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 140 mg once-daily
Trial: 20139391
Drug: Dasatinib 70
RxNorm normalized name: dasatinib 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 70 mg twice-daily
Trial: 20139391
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg once daily for 6 months without complete cytogenetic response
Trial: 18084015
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg once daily subcutaneously up to 8 days
Trial: 18084015
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (placebo or unfractionated heparin)
Trial: 18084015
Drug: Fondaparinux vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux vs. UF heparin infusion for 24-48 h
Trial: 16147905
Drug: Valsartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (160 mg/d) at bed-time
Trial: 16147905
Drug: Valsartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (160 mg/d) upon awakening
Trial: 10645371
Drug: Concurrent tasks
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent tasks (verbal, visual, spatial-sequential, spatial-simultaneous)
Trial: 1391736
Drug: Furazolidone (FZ)
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furazolidone (FZ) high dose, 2 week course
Trial: 31151239
Drug: Bilateral infraorbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral infraorbital and infratrochlear nerve block with 8 mL of 0.5% ropivacaine
Trial: 28845935
Drug: L-carnitine fumarate
RxNorm normalized name: L-carnitine fumarate
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine fumarate (1 g), acetyl-L-carnitine (0.5 g) twice daily, clomiphene citrate (CC) 25 mg twice daily, antioxidant complex (vitamins A, E, C, selenium, zinc)
Trial: 28845935
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 25 mg twice daily, antioxidant complex (vitamins)
Trial: 24874591
Drug: vildagliptin +
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: vildagliptin + metformin
Trial: 15155403
Drug: RTUF supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTUF supplement
Trial: 15155403
Drug: Maize/soy flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize/soy flour and RTUF supplement
Trial: 9220214
Drug: Buspirone 30
RxNorm normalized name: busPIRone 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 30 mg/d, administered twice a day (BID)
Trial: 9220214
Drug: Buspirone 30
RxNorm normalized name: busPIRone 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 30 mg/d, administered three times a day (TID)
Trial: 8345495
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg) after 48 hours of abstention
Trial: 8345495
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg) after 12 hours of abstention
Trial: 30478716
Drug: Microdose LSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdose LSD (5, 10, and 20 μg)
Trial: 24938502
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch + physical exercises
Trial: 24938502
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch alone
Trial: 22800889
Drug: Adenosine 50
RxNorm normalized name: adenosine 50 mcg/mL-NaCl 0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 50 µg×kg(‐1)×min(‐1) (low-dose group)
Trial: 22800889
Drug: Adenosine 70
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine 70 µg×kg(‐1)×min(‐1) (high-dose group)
Trial: 22800889
Drug: Saline 1
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 1 ml/min (control group)
Trial: 17698695
Drug: BHT‐3009 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHT‐3009 (0.5 mg, 1.5 mg, and 3 mg) administered as intramuscular injections at weeks 1, 3, 5, and 9
Trial: 17698695
Drug: BHT‐3009 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHT‐3009 with 80 mg of daily oral atorvastatin calcium
Trial: 12401614
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% (2 mL)
Trial: 12401614
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg, 2 mL)
Trial: 10363691
Drug: No induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No induction (no antithymocyte antibodies)
Trial: 7002427
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of timolol and AHCT
Trial: 7002427
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Timolol + AHCT)
Trial: 30410041
Drug: TELE‐IBD Weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TELE‐IBD Weekly
Trial: 28992296
Drug: Sacubitril/valsartan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 100 mg (increased to 200 mg at week 4, and 400 mg at week 10 if BP >140/90 mm Hg)
Trial: 28992296
Drug: Sacubitril/valsartan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (various doses as above)
Trial: 28992296
Drug: Olmesartan 10
RxNorm normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 10 mg (increased to 20 mg at week 4, and 40 mg at week 10 if BP >140/90 mm Hg)
Trial: 19426116
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies targeting different pathways of T-cell activation
Trial: 17539025
Drug: High HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High HBV DNA levels prior to chemotherapy
Trial: 15171772
Drug: Radiofrequency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency treatment on the left side of the face
Trial: 11356768
Drug: Aspirin (1,300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1,300 mg) with water placebo (WP)
Trial: 11356768
Drug: Aspirin (1,300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1,300 mg) with 6% CHO beverage
Trial: 11356768
Drug: Aspirin (1,300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1,300 mg) with 6% CHO+G beverage
Trial: 11356768
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P) with 6% CHO+G beverage
Trial: 10806751
Drug: mifepristone 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mifepristone 12.5 mg/day po for three months
Trial: 8283898
Drug: Heparin-coated extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated extracorporeal circuit (Duraflo II)
Trial: 17023704
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2 g) plus alpha-tocopherol (800 IU)
Trial: 3518646
Drug: Topical hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hypothermia with cold potassium cardioplegia (group 1)
Trial: 3518646
Drug: Topical hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hypothermia with local interruption of the coronary circulation (group 2)
Trial: 31078666
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 µg twice-daily
Trial: 31078666
Drug: Titrated insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated insulin glargine (iGlar)
Trial: 23689954
Drug: Augmentation Compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation Compression Plating (ACP)
Trial: 21244590
Drug: Osteopathy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathy treatment (specific dosage and duration not mentioned)
Trial: 19631303
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg GLP-2
Trial: 19631303
Drug: 1.6 mg
RxNorm normalized name: menthol 1.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg GLP-2
Trial: 19631303
Drug: 3.2 mg
RxNorm normalized name: menthol 3.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 mg GLP-2
Trial: 14634379
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin daily
Trial: 14634379
Drug: Oral floroglucine‐trimetossibenzene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral floroglucine‐trimetossibenzene 3 times daily
Trial: 10735806
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg urapidil
Trial: 10735806
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg meperidine